Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02160951
What this trial is testing

Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 13
Early research (Phase 1)Study completedNCT00710528
What this trial is testing

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)Acute Myeloid Leukemia (AML)+1 more
Gilead Sciences 192
Early research (Phase 1)Study completedNCT02182141
What this trial is testing

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Boehringer Ingelheim 17
Early research (Phase 1)Study completedNCT00594126
What this trial is testing

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Geron Corporation 20
Early research (Phase 1)Study completedNCT00664898
What this trial is testing

The Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 18
Early research (Phase 1)Active Not RecruitingNCT05259839
What this trial is testing

Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 283
Early research (Phase 1)Study completedNCT00996957
What this trial is testing

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Advanced Solid TumorsMultiple Myeloma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 37
Early research (Phase 1)Ended earlyNCT02400242
What this trial is testing

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 85
Testing effectiveness (Phase 2)Study completedNCT01001442
What this trial is testing

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Biotest Pharmaceuticals Corporation 35
Testing effectiveness (Phase 2)Study completedNCT03544281
What this trial is testing

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 153
Testing effectiveness (Phase 2)Active Not RecruitingNCT03933735
What this trial is testing

TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 220
Testing effectiveness (Phase 2)Looking for participantsNCT04634552
What this trial is testing

Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 510
Testing effectiveness (Phase 2)Looking for participantsNCT05714839
What this trial is testing

Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 123
Early research (Phase 1)Ended earlyNCT00744354
What this trial is testing

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
UNC Lineberger Comprehensive Cancer Center 32
Early research (Phase 1)Ended earlyNCT03031730
What this trial is testing

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Who this might be right for
PlasmacytomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Ended earlyNCT03567616
What this trial is testing

Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 8
Early research (Phase 1)WithdrawnNCT02951117
What this trial is testing

Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

Who this might be right for
Multiple Myeloma
AbbVie
Early research (Phase 1)Ended earlyNCT04244656
What this trial is testing

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
CRISPR Therapeutics AG 26
Early research (Phase 1)Study completedNCT04671251
What this trial is testing

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Avalo Therapeutics, Inc. 13
Testing effectiveness (Phase 2)UnknownNCT05308225
What this trial is testing

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sorrento Therapeutics, Inc. 72
Next Page